Cargando…
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
BACKGROUND: Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevacizumab is still very controversial. We report the outcome of 6 eyes of 4 premature infants with ROP stage 3 plus disease treated with ranibizumab monotherapy. METHODS: Six eyes of 4 premature infants with threshold ROP...
Autores principales: | Menke, Marcel N, Framme, Carsten, Nelle, Mathias, Berger, Markus R, Sturm, Veit, Wolf, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365803/ https://www.ncbi.nlm.nih.gov/pubmed/25886603 http://dx.doi.org/10.1186/s12886-015-0001-7 |
Ejemplares similares
-
Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016) -
Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity
por: Parchand, Swapnil M, et al.
Publicado: (2021) -
Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023) -
COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017) -
Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
por: Wu, Lei, et al.
Publicado: (2023)